Compare Stocks → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACXPNASDAQ:APLTNASDAQ:LVTXNASDAQ:SNSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$2.17+2.4%$2.32$1.17▼$8.82$34.20M-1.7981,130 shs32,860 shsAPLTApplied Therapeutics$4.76+5.1%$5.77$1.18▼$9.39$543.79M1.91729,569 shs622,610 shsLVTXLAVA Therapeutics$3.03-2.3%$2.92$1.13▼$6.47N/A0.69160,975 shs47,455 shsSNSESensei Biotherapeutics$1.79+8.5%$1.03$0.51▼$1.92$44.89M0.14322,135 shs721,654 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+2.36%+4.83%+8.50%-31.97%-21.38%APLTApplied Therapeutics+5.08%+11.21%-23.35%+57.62%+185.03%LVTXLAVA Therapeutics-2.26%+10.99%-2.57%+76.16%+100.66%SNSESensei Biotherapeutics+8.48%+75.49%+80.81%+120.99%+19.33%Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals1.0062 of 5 stars3.52.00.00.00.61.70.0APLTApplied Therapeutics4.7163 of 5 stars4.54.00.04.70.63.30.6LVTXLAVA Therapeutics1.8463 of 5 stars3.55.00.00.00.60.00.6SNSESensei Biotherapeutics4.4479 of 5 stars3.55.00.04.80.61.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals3.00Buy$12.00453.00% UpsideAPLTApplied Therapeutics3.00Buy$11.00131.09% UpsideLVTXLAVA Therapeutics3.00Buy$6.0098.02% UpsideSNSESensei Biotherapeutics3.00Buy$4.00123.46% UpsideCurrent Analyst RatingsLatest APLT, SNSE, LVTX, and ACXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.003/26/2024APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/21/2024LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/19/2024ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/15/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/6/2024APLTApplied TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $12.002/28/2024ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/22/2024APLTApplied TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/22/2024APLTApplied TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/16/2024APLTApplied TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AAPLTApplied Therapeutics$9.99M54.42N/AN/A($0.20) per share-23.80LVTXLAVA Therapeutics$6.77MN/AN/AN/A$3.39 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$1.15N/AN/AN/AN/A-289.69%-185.19%5/15/2024 (Confirmed)APLTApplied Therapeutics-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)LVTXLAVA Therapeutics-$41.97M-$1.59N/AN/AN/A-620.09%-68.54%-35.68%6/13/2024 (Estimated)SNSESensei Biotherapeutics-$34.10M-$1.22N/AN/AN/AN/A-44.01%-38.58%5/14/2024 (Estimated)Latest APLT, SNSE, LVTX, and ACXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024N/AACXPAcurx Pharmaceuticals-$0.24N/A+$0.24N/AN/AN/A 3/20/2024Q4 2023LVTXLAVA Therapeutics$0.16-$0.24-$0.40-$0.24$25.00 million$0.35 million3/15/2024Q4 2023ACXPAcurx Pharmaceuticals-$0.26-$0.38-$0.12-$0.38N/AN/A3/6/2024Q4 2023APLTApplied Therapeutics-$0.15-$0.33-$0.18-$0.33N/A($0.67) million2/28/2024Q4 2023SNSESensei Biotherapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.532.53APLTApplied TherapeuticsN/A0.760.76LVTXLAVA Therapeutics0.016.626.62SNSESensei Biotherapeutics0.0111.9211.92OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%APLTApplied Therapeutics98.31%LVTXLAVA TherapeuticsN/ASNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals35.30%APLTApplied Therapeutics19.10%LVTXLAVA Therapeutics0.79%SNSESensei Biotherapeutics25.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals415.76 million10.20 millionOptionableAPLTApplied Therapeutics25114.24 million92.42 millionOptionableLVTXLAVA Therapeutics37N/AN/AOptionableSNSESensei Biotherapeutics2825.08 million18.69 millionNot OptionableAPLT, SNSE, LVTX, and ACXP HeadlinesSourceHeadlineSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meetingglobenewswire.com - April 24 at 4:05 PMSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conferenceglobenewswire.com - April 9 at 7:30 AMSensei Biotherapeutics CFO Erin Colgan to resignuk.investing.com - April 4 at 11:42 PMSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironmentglobenewswire.com - April 4 at 4:05 PMSensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposiumglobenewswire.com - March 22 at 7:30 AMSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferencesglobenewswire.com - March 6 at 7:30 AMBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trialsmarkets.businessinsider.com - February 29 at 3:22 PMSensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlightsglobenewswire.com - February 28 at 7:30 AMSensei Biotherapeutics Announces Board Member Resignation and Consultant Rolemsn.com - February 9 at 10:35 AMSensei Biotherapeutics Streamlines Board, Appoints Interim Chairmsn.com - February 9 at 10:35 AMSensei Biotherapeutics to Present at Upcoming Conferencesfinance.yahoo.com - February 7 at 7:42 AMBuy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety Datamarkets.businessinsider.com - January 6 at 1:14 AMSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestonesfinance.yahoo.com - January 4 at 8:07 AMThe Potential Rise in the Price of Sensei Biotherapeutics Inc (SNSE) following insiders activityknoxdaily.com - January 1 at 9:39 AMAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)markets.businessinsider.com - December 4 at 10:40 PMHC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy Recommendationmsn.com - December 4 at 10:40 PMKeeping an Eye on Sensei Biotherapeutics Inc (SNSE) After Insider Trading Activityknoxdaily.com - November 7 at 2:19 PMSensei Biotherapeutics GAAP EPS of -$0.28 in-linemsn.com - November 7 at 9:19 AMSensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlightsfinance.yahoo.com - November 7 at 9:19 AMSensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Resultsfinance.yahoo.com - November 7 at 9:19 AMSensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meetingfinance.yahoo.com - November 3 at 8:51 PMSensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meetingfinance.yahoo.com - October 25 at 2:01 PMRockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaqbizjournals.com - October 24 at 2:01 PMSensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023finance.yahoo.com - October 23 at 8:01 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcurx PharmaceuticalsNASDAQ:ACXPAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Applied TherapeuticsNASDAQ:APLTApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.LAVA TherapeuticsNASDAQ:LVTXLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.